SROs
DRAP issued Consolidated Notification for Regulatory Fees
Drug Regulatory Authority of Pakistan (DRAP) issued a consolidated notification of Regulatory fess for various functions and services. This notification is issued under the section (1) of section 20 of the Drug Regulatory Authority of Pakistan Act, 2012 (XX.I of 2012) read with sub-rule (3) of rule 4 of the Drug Regulatory Authority of Pakistan (Fee and Levy) Rules, 2022, and in supersession of all such previous Notifications. The Drug Regulatory Authority of Pakistan with the approval of the Policy Board has specified these regulatory fees. The Notification is provided as under: –
SRO 224(I)/2023: Notification of Amendment in the Medical Devices Rules, 2017 dated 27th February, 2023
SRO 209(I)/2023 dated 21st Feb, 2023: Fixation of Maximum Retail Price (MRP) of Drugs
SRO 208(I)/2023 dated 21st Feb, 2023: Fixation of Maximum Retail Price (MRP) of Drugs
SRO 207(I)/2023 dated 21st Feb, 2023: Fixation of Maximum Retail Price (MRP) of Drugs
SRO 24(I)/2023. Maximum Retail Price (MRP) Fixation of twenty (20) Drugs dated 11th January, 2023
Notification – SRO 1995(I)/2022 MRP of Paracetamol
S.R.O. 1083(I)/2022 (Maximum retail price of Remdesivir injection)
Draft amendments in rules framed under Drug Act 1976 (for comments within 7 days of publication of SRO).
S.R.O 1084(I)/2022 (Amendments in drugs (Appellate Board) rules 1976)
S.R.O 1085(I)/2022 (Amendments in drugs (Import and Export) rules 1976)
S.R.O 1086(I)2022 (Amendments in drugs (Federal Inspectors, Federal Drug Laboratory, Federal Government Analysts)) rules 1976
S.R.O 1087(I)/2022(Amendments in drugs (Licensing, Registering, Advertising) rules 1976)